Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167425 | 0.85 | SMN1; SMN2 (0.49) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL14139047 | 0.84 | ALDH1A1 (0.55) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL4324414 | 0.82 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL17288867 | 0.82 | PLA2G4A (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL6314796 | 0.80 | SMN1; SMN2 (0.51) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL29625285 | 0.80 | SMN1; SMN2 (0.55) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL31373302 | 0.80 | KDM4C (0.58) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL31373301 | 0.80 | KDM4C (0.58) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL31708827 | 0.79 | ALDH1A1 (0.51) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL10133288 | 0.79 | ALDH1A1 (0.63) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-111108109-A | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-05-05 | — | — | CN | claimed |
| US-20260028316-A1 | Biphenyl and Phenylpyridine Compounds | PFIZER INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4665454-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250333423-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS | CARTHRONIX INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12421212-B2 | Substituted benzenecarboxamides as IL-17A modulators | DICE ALPHA, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| US-20250188030-A1 | Biphenyl and Phenylpyridine Compounds | PFIZER INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4511378-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS | Carthronix, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12234225-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20060287295-A1 | Quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-7056934-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1654234-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-10 | — | — | EP | disclosed |
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2005009965-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188030-A1 | Biphenyl and Phenylpyridine Compounds | CYP1B1, CYP1A1, PAH | ALDH1A1 39/4885CYP1A2 9/4885CYP2C9 28/4885 |
| US-20060287295-A1 | Quinazoline derivatives as antiproliferative agents | MKI67, CCNI, ERBB2 | ALDH1A1 2427/4885CYP1A2 1108/4885CYP2C9 2667/4885 |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | ALDH1A1 4346/4885CYP1A2 4436/4885CYP2C9 4840/4885 |
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | ALDH1A1 284/4885CYP1A2 436/4885CYP2C9 767/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | ALDH1A1 1580/4885CYP1A2 336/4885CYP2C9 207/4885 |
| US-12234225-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | ALDH1A1 951/4885CYP1A2 1937/4885CYP2C9 3910/4885 |
| US-20250333423-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS | STAT3, STAT1, STAT4 | ALDH1A1 3979/4885CYP1A2 4831/4885CYP2C9 4865/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALDH1A1 656/4885CYP1A2 1091/4885CYP2C9 1658/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | ALDH1A1 2147/4885CYP1A2 4673/4885CYP2C9 4275/4885 |
| US-12421212-B2 | Substituted benzenecarboxamides as IL-17A modulators | IL17A, IL2, IL23R | ALDH1A1 505/4885CYP1A2 231/4885CYP2C9 864/4885 |
| US-20260028316-A1 | Biphenyl and Phenylpyridine Compounds | KAT2B, KAT2A, KAT6A | ALDH1A1 1348/4885CYP1A2 405/4885CYP2C9 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.